Kinetic Insights
Factual, cited reporting on emerging peptide research developments. Published weekly.
Lilly Expands Pre-Approval Access to Retatrutide
Eli Lilly is broadening pre-approval access to its investigational triple-agonist retatrutide. What the eligibility criteria, timeline, and open questions are.
8 August 2026
Can You Reduce GLP-1 Doses After Weight Loss?
A Scripps Health study found 30 of 34 patients maintained weight loss by halving their GLP-1 injection frequency. Findings published in the Journal of Obesity.
5 August 2026
TGA Escalates Peptide Enforcement as FDA Moves Toward Broader Compounding Access
The TGA is intensifying enforcement against unapproved peptide imports and promotion, while the FDA moves toward broader compounding access. Two regulatory paths diverge.
1 August 2026
FDA Advisory Panel Narrowly Votes to Add Six Peptides to Compounding List
FDA advisory panel narrowly voted to add six of seven peptides to the national compounding list, overriding its own scientists' safety concerns in close votes.
29 July 2026
As FDA Opens Peptide Access, Australia Tightens Its Regulatory Grip
The FDA just voted to expand peptide compounding access in the US. Australia's TGA is moving in the opposite direction. What the trans-Pacific regulatory divergence means.
29 July 2026
FDA Peptide Panel Faces Scrutiny Before July Meeting
FDA scientists oppose peptide access expansion ahead of a July 23-24 advisory committee meeting. Panel composition draws scrutiny.
12 July 2026
Three Charged After $2 Million Peptide and Steroid Seizure in Victoria
Australian Border Force and TGA seized $2 million worth of steroids and peptides in Melbourne after an eight-month investigation. Three Victorians charged.
27 June 2026
FDA Advisory Committee to Review BPC-157 and Six Other Unapproved Peptides
An FDA advisory committee will consider whether pharmacies may compound BPC-157 and six other unapproved peptides. What the review means for peptide regulation.
8 June 2026
Retatrutide Meets Endpoints in Pivotal TRIUMPH-1 Trial
Eli Lilly's triple-agonist retatrutide met its primary and key secondary endpoints in the 80-week TRIUMPH-1 obesity trial. What the topline data show.
3 June 2026
The Amylin Pathway Steps Forward as a Distinct Research Frontier
Amylin-receptor agonists are emerging as a distinct obesity research frontier. What petrelintide's ZUPREME-1 Phase 2 readout means for the class.
3 June 2026
A Five-Receptor Peptide Conjugate Enters the Research Conversation
A research team has linked a GLP-1/GIP peptide to a PPAR ligand, creating a conjugate that activates five receptors. Early preclinical findings explained.
3 June 2026
Oral GLP-1 Agonists: What the Shift from Injectables Means for Research
The first oral GLP-1 receptor agonist for obesity has reached the market. What the shift from injectables means for incretin research.
1 June 2026
CVS Caremark Deal Restores Lilly's Obesity Drug Coverage, Reshapes Market Access
CVS Caremark's new formulary agreement with Eli Lilly covers Foundayo and restores Zepbound preferred status, ending Novo Nordisk's exclusive placement.
28 May 2026
Kailera's Triple-G Obesity Compound Shows Early-Stage Promise
Phase 1 data from Kailera Therapeutics and Hengrui Medicine suggest their triple agonist may outperform retatrutide in early-stage comparisons.
21 May 2026
Scaling Peptide Manufacturing: CMC Challenges in a Rapidly Expanding Market
Demand for GLP-1 agonists is straining global peptide manufacturing capacity. A look at the chemistry, manufacturing, and controls challenges facing the supply chain.
14 May 2026
Sleep, Peptides, and Appetite: How Circadian Biology Influences Metabolic Research
Sleep restriction alters ghrelin, leptin, and GLP-1 signalling. Understanding circadian peptide dynamics is becoming relevant to metabolic drug development.
7 May 2026Preclinical Obesity Models and Their Translational Limitations
Mouse models of obesity have driven the field for decades, but their translational relevance is limited. How researchers are improving the predictive value of preclinical studies.
30 April 2026
Lean Mass Preservation During Pharmacological Weight Loss: An Unresolved Research Question
Weight loss from GLP-1 agonists includes both fat and lean mass. Current research examines the magnitude of lean mass loss and whether adjunct therapies can mitigate it.
23 April 2026
Navigating the FDA Regulatory Pathway for Obesity Peptide Therapeutics
The FDA's evolving framework for obesity drug approval reflects the complexity of a fast-moving field. An overview of regulatory expectations for peptide developers.
16 April 2026
Copper Peptides in Tissue Research: What the Preclinical Data Actually Show
GHK-Cu is widely discussed in the context of tissue repair and skin biology. A review of the preclinical evidence and what remains unvalidated in human studies.
9 April 2026
Peptide Bioconjugation: Linking Molecules to Extend Half-Life and Target Tissues
Bioconjugation strategies, from albumin binding to PEGylation and lipidation, are central to extending peptide half-life. How researchers are engineering next-generation conjugates.
2 April 2026
How Obesity Clinical Trial Design Is Evolving Alongside the Drug Pipeline
As obesity drug candidates multiply, trial design must adapt. A look at endpoint selection, comparator arms, and the challenges of long-duration studies.
26 March 2026GLP-1 Receptor Agonists: Mechanisms Beyond Appetite Suppression
GLP-1 receptor agonists affect more than appetite. Emerging research maps their action on gastric motility, hepatic metabolism, and central reward circuits.
19 March 2026Advances in Peptide Stability and Gut Absorption: Overcoming the Oral Bioavailability Challenge
New formulation strategies are improving oral bioavailability of peptide drugs. A look at the absorption enhancer technologies reshaping how researchers approach oral delivery.
12 March 2026